Physician profile
Donna M Pinelli
NPI 1023019023
$1,361.81
in general payments reported to CMS, 2019-2025
12 companies · $67.27 in 2025
The $67.27 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $141 · 2021: $33.48 · 2022: $83.55 · 2023: $15.16 · 2024: $433 · 2025: $67.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $504.46 | 2019-2024 | Lynparza |
| Tempus Ai, INC | $227.07 | 2024 | Xt Cdx |
| Abbvie INC. | $213.28 | 2019-2025 | |
| Genentech USA, INC. | $102.26 | 2019 | |
| Merck Sharp & Dohme LLC | $73.97 | 2019-2023 | Keytruda, Lynparza |
| Coloplast Corp | $62.63 | 2019 | |
| Myriad Genetic Laboratories, INC. | $47.53 | 2020-2022 | |
| Intuitive Surgical, INC. | $44.03 | 2019 | |
| Adaptive Biotechnologies Corporation | $25.36 | 2024 | Clonoseq |
| Glaxosmithkline, LLC. | $24.23 | 2022 | |
| Daiichi Sankyo INC. | $21.62 | 2022 | |
| On Target Laboratories, INC | $15.37 | 2025 | Cytalux |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Pinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.